scholarly journals Psychological therapies for bipolar disorder – adjunct not alternative to pharmacological treatments

2011 ◽  
Vol 35 (5) ◽  
pp. 196-196 ◽  
Author(s):  
Sumeet Gupta ◽  
Johanna Brown
Keyword(s):  
Bipolar Disorder ◽  
Pharmacological Treatments ◽  
Psychological Therapies

scholarly journals Psychological therapies and psychoeducational recommendations for bipolar disorder treatment during COVID‐19 pandemic

2020 ◽  
Vol 22 (6) ◽  
pp. 644-646
Author(s):  
Luisa Siqueira Rotenberg ◽  
Camila Nascimento ◽  
Tatiana Cohab Khafif ◽  
Rodrigo Silva Dias ◽  
Beny Lafer
Keyword(s):  
Bipolar Disorder ◽  
Psychological Therapies ◽  
Disorder Treatment

scholarly journals Psychosis in Alzheimer’s Disease

2020 ◽  
Vol 20 (12) ◽  
Author(s):  
Clive Ballard ◽  
Helen C. Kales ◽  
Constantine Lyketsos ◽  
Dag Aarsland ◽  
Byron Creese ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Atypical Antipsychotics ◽  
Cholinesterase Inhibitors ◽  
Pharmacological Treatments ◽  
Muscarinic Agonists ◽  
Pharmacological Management ◽  
Psychological Therapies ◽  
New Treatment

Abstract Purpose of Review To review the incidence, treatment and genetics of psychosis in people with mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Recent Findings Psychosis in Alzheimer’s disease (AD) has an incidence of ~ 10% per year. There is limited evidence regarding psychological interventions. Pharmacological management has focused on atypical antipsychotics, balancing modest benefits with evidence of long-term harms. The 5HT2A inverse agonist pimavanserin appears to confer benefit in PD psychosis with initial evidence of benefit in AD. Cholinesterase inhibitors give modest benefits in DLB psychosis. The utility of muscarinic agonists, lithium, glutamatergic and noradrenergic modulators needs further study. Summary Recent work has confirmed the importance of psychosis in MCI as well as AD. The lack of evidence regarding psychological therapies is an urgent knowledge gap, but there is encouraging evidence for emerging pharmacological treatments. Genetics will provide an opportunity for precision medicine and new treatment targets.

scholarly journals The capacity of schizophrenia and bipolar disorder individuals to make autonomous decisions about pharmacological treatments for their illness in real life: A scoping review

2020 ◽  
Vol 3 (3) ◽  
Author(s):  
Enric Vincens Pons ◽  
Luis Salvador‐Carulla ◽  
Alfredo Calcedo‐Barba ◽  
Silvia Paz ◽  
Thomas Messer ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Scoping Review ◽  
Real Life ◽  
Pharmacological Treatments

Psychopharmacological Treatments for Bipolar Disorder

2020 ◽  
pp. 191-232
Author(s):  
Stephen M. Strakowski ◽  
Jorge R. C. Almeida ◽  
Melissa P. DelBello
Keyword(s):  
Bipolar Disorder ◽  
Treatment Options ◽  
Mood States ◽  
Acute Mania ◽  
Evidence Based ◽  
Pharmacological Treatments ◽  
Bipolar Illness ◽  
The Past ◽  
Psychiatric Conditions ◽  
Third Line

The discovery of lithium in 1946 led to a revolution in the management of bipolar disorder as well as other psychiatric conditions. Since that time and especially in the past 20 years, treatment options for bipolar disorder have progressively advanced such that a modern practitioner has a number of evidence-based options to manage the illness. However, the evidence is strongest in adults for acute mania and weakens in other mood states and in youth. Nonetheless, based on the available evidence, this chapter provides recommendations for first-, second-, and third-line pharmacological treatments for bipolar illness to guide clinicians. Additionally, specific considerations for the various medications are reviewed. Suggestions are provided for both adults and youth.

scholarly journals Psychological therapies for bipolar disorder: addressing some misunderstandings

2011 ◽  
Vol 35 (11) ◽  
pp. 432-434
Author(s):  
Steven H. Jones ◽  
Fiona Lobban ◽  
Anne Cooke ◽  
Warren Mansell ◽  
Kim Wright ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Psychological Therapies

The management of treatment-resistant bipolar disorder

2017 ◽  
Author(s):  
Salih Selek ◽  
Ives Cavalcante Passos ◽  
Jair C. Soares
Keyword(s):  
Bipolar Disorder ◽  
Treatment Resistance ◽  
Pole Position ◽  
Short Description ◽  
Evidence Based ◽  
Pharmacological Treatments ◽  
Mixed States ◽  
Treatment Resistant ◽  
Future Directions ◽  
Depressive Episodes

Treatment-resistant bipolar disorder is a challenging area in clinical psychiatry and both defining treatment resistance and managing it is difficult despite new emerging pharmacological and non-pharmacological treatments. This chapter revisits the definition in treatment resistance in bipolar and summarizes the general recommendations in treatment-resistant bipolar disorder by taking revision of the guidelines to ‘pole position’. Manic and depressive episodes are covered in different subtitles. A short description of the complementary and alternative treatments is also mentioned. Special conditions in treatment resistance including co-morbidities, mixed states, and substance abuse are discussed separately. Future directions are also addressed by both evidence-based and naturalistic findings. Final recommendations for mania and depression are discussed after each subtitle and illustrated with a figure to give readers a visual summary.

Sign in / Sign up

Export Citation Format

Share Document